# A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

> **NCT07693868** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 128 (estimated)

## Conditions studied

- Obesity
- Elevated High-sensitivity C-reactive Protein (hsCRP)

## Interventions

- **DRUG:** NNC6022-0004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07693868
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2027-08-03
- **Final completion:** 2027-08-03
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693868, "A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*